Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Transforming growth factor beta-mediated micromechanics modulates disease progression in primary myelofibrosis

Journal article

Teodorescu P. et al, (2020), JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 24, 11100 - 11110

Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis

Journal article

Tomuleasa C. et al, (2018), Journal of Cellular Physiology, 233, 422 - 433

PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative

Journal article

Gafencu GA. et al, (2017), Medical Hypotheses, 104, 30 - 34

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy

Journal article

Tomuleasa C. et al, (2016), International Journal of Nanomedicine, 641 - 641